IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC
Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer
Trastuzumab Combo Shows Numerical Survival Benefit in Gastric/GEJ Cancer
Telotristat Ethyl Plus Chemo May Stabilize Weight in Metastatic PDAC